Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FASLODEX | AstraZeneca | N-021344 RX | 2002-04-25 | 1 products, RLD, RS |
FULVESTRANT | Fresenius Kabi | N-210326 RX | 2019-05-20 | 1 products |
FULVESTRANT | Teva | N-210063 RX | 2019-08-19 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
faslodex | New Drug Application | 2020-10-01 |
fulvestrant | ANDA | 2024-01-16 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 76 | 201 | 59 | 10 | 42 | 357 |
Triple negative breast neoplasms | D064726 | — | — | 9 | 20 | 2 | 1 | — | 27 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | 3 | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 22 | 14 | 2 | — | 2 | 32 |
Male breast neoplasms | D018567 | — | — | — | 3 | 3 | — | 1 | 7 |
Invasive hydatidiform mole | D002820 | — | D39.2 | 3 | 2 | 1 | — | — | 5 |
Ductal carcinoma breast | D018270 | — | — | 1 | 1 | 1 | — | — | 2 |
Neoadjuvant therapy | D020360 | — | — | — | 1 | 1 | — | — | 1 |
Progression-free survival | D000077982 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 7 | 6 | — | — | — | 10 |
Non-small-cell lung carcinoma | D002289 | — | — | 5 | 5 | — | — | — | 8 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 6 | — | — | — | 7 |
Prostatic neoplasms | D011471 | — | C61 | 2 | 4 | — | — | — | 5 |
Urologic neoplasms | D014571 | — | C64-C68 | 1 | 2 | — | — | — | 2 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | — | — | — | 2 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 2 | — | — | — | 2 |
Uterine cervical neoplasms | D002583 | HP_0030159 | — | 1 | 1 | — | — | — | 2 |
Liposarcoma | D008080 | — | — | 2 | 1 | — | — | — | 2 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 2 | — | — | — | — | 2 |
Ovarian epithelial carcinoma | D000077216 | — | — | 2 | — | — | — | — | 2 |
Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | — | — | — | — | 2 |
Endometrioid carcinoma | D018269 | — | — | 1 | — | — | — | — | 1 |
Fallopian tube neoplasms | D005185 | — | — | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Malignant mesothelioma | D000086002 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Postmenopause | D017698 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Fulvestrant |
INN | fulvestrant |
Description | Fulvestrant is a 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer. It has a role as an antineoplastic agent, an estrogen receptor antagonist and an estrogen antagonist. It is a 3-hydroxy steroid, a 17beta-hydroxy steroid, an organofluorine compound and a sulfoxide. It derives from a hydride of an estrane. |
Classification | Small molecule |
Drug class | estrogens; estrogen antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O |
PDB | — |
CAS-ID | 129453-61-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1358 |
ChEBI ID | 31638 |
PubChem CID | 104741 |
DrugBank | DB00947 |
UNII ID | 22X328QOC4 (ChemIDplus, GSRS) |